“These observations beg the question of whether manufacturers leveraging federal incentives to bring pediatric drugs to market should be held to a reasonable expectation of accessibility irrespective of the effective patent life remaining at the time of pediatric approval,” researchers said. “Manufacturers, clinicians, and regulators should collaborate to explore solutions that may lead to improved medication options for pediatric patients.”